secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001193125-24-160146
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO appoints COO Curran Simpson as CEO; founder Kenneth Mills becomes Chairman
--------------------------------------------------------------------------------

- Curran Simpson, former COO, appointed President and CEO effective July 1, 2024; also named to Board.
- Co-founder Kenneth Mills steps down as CEO, becomes Chairman of the Board; advisor until June 2025.
- Simpson's compensation: base salary $610k, bonus target 60%, equity grant $2.5M (75% options, 25% RSUs).
- Daniel Tassé appointed Lead Independent Director, replacing Jerry Karabelas.
- Company reiterates cash guidance: $380.5M as of March 31, 2024, funding ops into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/d718851d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-160146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer